REVIEW

It’s About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
Jason R. Westin and Razelle Kurzrock

THERAPEUTIC DISCOVERY

Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel
Diana M. Cittelly, Irina Dimitrova, Erin N. Howe, Dawn R. Cochrane, Annie Jean, Nicole S. Spoelstra, Monique A. Spellman, and Jennifer K. Richer

Dual Systemic Tumor Targeting with Ligand-Directed Phage and Grp78 Promoter Induces Tumor Regression
Azadeh Kia, Justyna M. Przystal, Nastasia Nianiaris, Nicholas D. Mazarakis, Paul J. Mintz, and Amin Hajitou

DLL4-Fc, an Inhibitor of DLL4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity

PRECLINICAL DEVELOPMENT

Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, and David A. Proia

BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Niranjan Awasthi, Changhua Zhang, Winston Ruan, Margaret A. Schwarz, and Roderich E. Schwarz

Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
Joanna Keating, Maria Tsoli, Andrew R. Hallahan, Wendy J. Ingram, Michelle Haber, and David S. Ziegler
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich, Tobias Raum, Ralf Lutterbuese, Markus Voelkel, Petra Deegen, Doris Rau, Roman Kischel, Patrick Hoffmann, Christian Brandl, Joachim Schuhmacher, Peter Mueller, Ricarda Finnern, Melanie Fuergut, Dieter Zopf, Jerry W. Slootstra, Patrick A. Baueuerle, Benno Rattel, and Peter Kufer

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Jerome Moreaux, Thierry Remé, Wim Leonard, Jean-Luc Veyrune, Guilhem Requinand, Hartmut Goldschmidt, Dirk Hose, and Bernard Klein

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
Angela Romanelli, Anderson Clark, Franck Assayag, Sophie Chateau-Joubert, Marie-France Poupon, Jean-Luc Servely, Jean-Jacques Fontaine, Xiaohong Liu, Edward Spooner, Samantha Goodstal, Patricia de Cremoux, Ivan Bièche, Didier Decaudin, and Elisabetta Marangoni

SPOTLIGHT ON CLINICAL RESPONSE

Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefferd, Richard A. Scodyer, and Georgina V. Long

Acknowledgment to Reviewers

ABOUT THE COVER

Olfactomedin-like 3 (Olfml3), a proangiogenic cue and a BMP4 agonist, is produced by both tumor endothelial cells and accompanying pericytes and deposited in the perivascular compartment. Blocking Olfml3 regresses the tumor vasculature, decreases pericyte coverage, and inhibits the progression of tumors. Olfml3 blockade provides an alternative strategy to control tumor growth by targeting a single molecule that affects two distinct cell types within the tumor microenvironment. For details, see article by Miljkovic-Licina and colleagues on page 2588.